Randomised, double-blind, multicentre, phase Ⅰ/Ⅱ dose escalation and expansion trial of GR1501 in patients with plaque psoriasis: study protocol. Issue 11 (24th November 2020)

• Record Type: Journal Article
• Authors: Dong, Wenliang; Nie, Xiaoyan; Wang, Jiaxue; Xia, Lin; Cai, Lin; Wang, Qian; Wang, Wei; Fu, Weixing; Wang, Qi; Shen, Tiantian; Fan, Huaying; Niu, Suping; Cui, Yimin; Zheng, Qingshan; Zhang, Jianzhong; Fang, Yi
• Is Part Of: BMJ open. Volume 10:Issue 11(2020)
• Publication Date: 2020-11-24
• Subjects: clinical pharmacology -- psoriasis -- clinical trials; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2020-039067
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Psoriasis is a life-long, immune-mediated disease that greatly reduces the quality of life of patients. Plaque psoriasis is the most common form of psoriasis. Treatment options for plaque psoriasis with good tolerance and sufficient response remain profoundly limited. Based on mechanistic findings that suggest the key pathogenic role of interleukin (IL)-17 in plaque psoriasis, we hypothesise that GR1501, a new monoclonal antibody (IL-17A targeted), will be an efficacious treatment for plaque psoriasis. This phase I/II trial aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of GR1501. Methods and analysis: A multicentre, randomised, double-blind, phase I/II dose escalation and expansion trial will be conducted at four hospitals in China. In total, 226 patients with plaque psoriasis will be enrolled in the study, with 46 cases in the dose-escalation stage and 180 cases randomised to GR1501 or the placebo in a 3:1 ratio in the expansion cohort. The primary outcomes are safety and tolerability; the secondary outcomes include pharmacokinetics, immunogenicity and efficacy. Ethics and dissemination: The study is in accordance with the Declaration of Helsinki, and the ethics approvals of the protocol have been obtained from the ethics committees of all participating centres, including Peking University People's Hospital, Chinese PLA General Hospital, The First Affiliated Hospital, College of Medicine, Zhejiang University and the Second Xiangya Hospital of Central South University. The findings of the study will be presented in published journals or at scientific conferences or meetings. Trial registration number: ChiCTR1800017956.